Antibody data
- Antibody Data
- Antigen structure
- References [10]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- Q10056 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD14 Monoclonal Antibody (TuK4), Qdot™ 655
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Qdot™ Antibody (Ab) conjugates possess a bright fluorescence emission that makes them well suited for the detection of low-abundance extracellular proteins. Approximately the same size as R-phycoerythrin (R-PE) and compatible with existing organic fluorophore conjugates, Qdot™ Ab conjugates can be excited with any wavelength below their emission maximum, but are best excited by UV or violet light. The narrow, symmetric emission profiles of Qdot Ab conjugates allow for minimal compensation when using a single excitation source, and the very long stoke shifts enable better, more efficient multicolor assays using the 405 nm violet laser. Available in multiple colors for use in flow cytometry, these advantages make Qdot Ab conjugates powerful tools for antibody labeling and staining. Staining: Stain cells in any standard staining buffer, such as phosphate buffered saline (PBS) with 1% bovine serum albumin (BSA). We recommend analysis of cells within 18 hours of staining. If dilute reagent is used, dilute only the quantity of reagent to be used within one day. Qdot Ab conjugates may be mixed with other antibodies, but use the diluted conjugates on the day of dilution. Qdot Ab conjugates can be used for surface staining applications with most conventional sample preparation reagents, such as Cal-Lyse™ Lysing Solution and FIX & PERM™ reagents, with minimal effect on fluorescence. We have observed some batches of BD FACS™ Lysing Solution to interfere with Qdot Ab conjugate fluorescence. Each lot has been tested by flow cytometry using human peripheral blood leukocytes. The isotype control for this antibody is mouse IgG2a, Cat. No. Q10015.
- Antibody clone number
- TuK4
Submitted references IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer.
The classical NLRP3 inflammasome controls FADD unconventional secretion through microvesicle shedding.
Transdifferentiation of Human Circulating Monocytes Into Neuronal-Like Cells in 20 Days and Without Reprograming.
Detailed characterization of human Mycobacterium tuberculosis specific HLA-E restricted CD8(+) T cells.
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.
Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia.
Increased mucosal CD4+ T cell activation in rhesus macaques following vaccination with an adenoviral vector.
Pivotal role of M-DC8⁺ monocytes from viremic HIV-infected patients in TNFα overproduction in response to microbial products.
DNA-based HIV vaccines do not induce generalized activation in mucosal tissue T cells.
Leukocyte composition of human breast cancer.
Markov SD, Caffrey TC, O'Connell KA, Grunkemeyer JA, Shin S, Hanson R, Patil PP, Shukla SK, Gonzalez D, Crawford AJ, Vance KE, Huang Y, Eberle KC, Radhakrishnan P, Grandgenett PM, Singh PK, Madiyalakan R, Daniels-Wells TR, Penichet ML, Nicodemus CF, Poole JA, Jaffee EM, Hollingsworth MA, Mehla K
Molecular cancer therapeutics 2021 Dec;20(12):2457-2468
Molecular cancer therapeutics 2021 Dec;20(12):2457-2468
The classical NLRP3 inflammasome controls FADD unconventional secretion through microvesicle shedding.
Mouasni S, Gonzalez V, Schmitt A, Bennana E, Guillonneau F, Mistou S, Avouac J, Ea HK, Devauchelle V, Gottenberg JE, Chiocchia G, Tourneur L
Cell death & disease 2019 Feb 25;10(3):190
Cell death & disease 2019 Feb 25;10(3):190
Transdifferentiation of Human Circulating Monocytes Into Neuronal-Like Cells in 20 Days and Without Reprograming.
Bellon A, Wegener A, Lescallette AR, Valente M, Yang SK, Gardette R, Matricon J, Mouaffak F, Watts P, Vimeux L, Yun JK, Kawasawa YI, Clawson GA, Blandin E, Chaumette B, Jay TM, Krebs MO, Feuillet V, Hosmalin A
Frontiers in molecular neuroscience 2018;11:323
Frontiers in molecular neuroscience 2018;11:323
Detailed characterization of human Mycobacterium tuberculosis specific HLA-E restricted CD8(+) T cells.
Prezzemolo T, van Meijgaarden KE, Franken KLMC, Caccamo N, Dieli F, Ottenhoff THM, Joosten SA
European journal of immunology 2018 Feb;48(2):293-305
European journal of immunology 2018 Feb;48(2):293-305
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.
Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, Alvarado MD, Wolf DM, Bogunovic D, Bhardwaj N, Daud AI, Ha PK, Ryan WR, Pollack JL, Samad B, Asthana S, Chan V, Krummel MF
Nature medicine 2018 Aug;24(8):1178-1191
Nature medicine 2018 Aug;24(8):1178-1191
Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia.
Sander FE, Rydström A, Bernson E, Kiffin R, Riise R, Aurelius J, Anderson H, Brune M, Foà R, Hellstrand K, Thorén FB, Martner A
Oncotarget 2016 Feb 16;7(7):7586-96
Oncotarget 2016 Feb 16;7(7):7586-96
Increased mucosal CD4+ T cell activation in rhesus macaques following vaccination with an adenoviral vector.
Bukh I, Calcedo R, Roy S, Carnathan DG, Grant R, Qin Q, Boyd S, Ratcliffe SJ, Veeder CL, Bellamy SL, Betts MR, Wilson JM
Journal of virology 2014 Aug;88(15):8468-78
Journal of virology 2014 Aug;88(15):8468-78
Pivotal role of M-DC8⁺ monocytes from viremic HIV-infected patients in TNFα overproduction in response to microbial products.
Dutertre CA, Amraoui S, DeRosa A, Jourdain JP, Vimeux L, Goguet M, Degrelle S, Feuillet V, Liovat AS, Müller-Trutwin M, Decroix N, Deveau C, Meyer L, Goujard C, Loulergue P, Launay O, Richard Y, Hosmalin A
Blood 2012 Sep 13;120(11):2259-68
Blood 2012 Sep 13;120(11):2259-68
DNA-based HIV vaccines do not induce generalized activation in mucosal tissue T cells.
Reuter MA, Yuan S, Marx PA, Kutzler MA, Weiner DB, Betts MR
Human vaccines & immunotherapeutics 2012 Nov 1;8(11):1648-53
Human vaccines & immunotherapeutics 2012 Nov 1;8(11):1648-53
Leukocyte composition of human breast cancer.
Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM
Proceedings of the National Academy of Sciences of the United States of America 2012 Feb 21;109(8):2796-801
Proceedings of the National Academy of Sciences of the United States of America 2012 Feb 21;109(8):2796-801
No comments: Submit comment
No validations: Submit validation data